IT之家 6 月 24 日消息，
Samsung Electronics today announced a partnership with Alcedis, a digital-first clinical research organization (CRO) specializing in data-driven clinical trials, to translate biometrics collected by wearable devices into meaningful evidence for clinical trials in pharmaceutical and other research organizations, maximizing efficiency in terms of both cost and time.
Wearable technologies have become a widely available and cost-effective way to capture continuous, real-world health data, making them extremely appealing for clinical research. However, many research programs struggle to translate wearable-generated signals into clinically meaningful evidence.
Samsung addresses this challenge through an integrated approach that combines its latest advancements in wearable technology with clinically validated measurements, including bioelectrical impedance analysis ( BIA ) and electrodermal activity ( EDA ), as well as Software as a Medical Device ( SaMD ) features such as obstructive sleep apnea ( OSA ) and atrial fibrillation ( AFib ) detection, biomarker development expertise and research-related technical infrastructure designed to support evidence generation across the research lifecycle.
“The future of clinical research is increasingly collaborative and brings together technology, scientific expertise and research partners to generate a deeper understanding of human health,” said Jongmin Choi, Head of Health R&D Group, Mobile eXperience ( MX ) Business, Samsung Electronics. “Through our collaboration with Alcedis, Samsung is unlocking new opportunities for biomarker development, digital endpoint innovation and evidence generation throughout the research lifecycle.”
Samsung’s research platform starts with its cutting-edge devices and biosensors featured on Galaxy Watch that enable continuous collection of physiological data in real-world environments for users that have consented. With industry-leading wearable technology and a collaborative approach to developing measurement methodologies that provide a foundation for scientifically meaningful digital biomarkers and endpoints, Samsung’s research platform allows for faster study setup with fine-grained control of biosensors and access to participant- and device-level insights and biosensor data with respect to the study and established protocols.
As healthcare shifts toward more connected, data-driven models of care and research, Samsung is helping bridge the gap between everyday health monitoring and scientific discovery — enabling a new era of evidence generation that brings researchers closer to real-world insights and helps accelerate innovation across the healthcare ecosystem.
“The future of clinical research depends on our ability to capture meaningful health data beyond traditional clinical settings,” said Hanno Härtlein, CEO of Alcedis. “Our collaboration with Samsung brings together complementary strengths and scalable infrastructure to help advance endpoints and biomarker development, to accelerate evidence generation and support the development of more patient-centric healthcare innovations. Under our collaboration, Alcedis will lead study execution and participant engagement, while Samsung will provide its advanced wearable technology and research infrastructure to support evidence generation.”
广告声明：文内含有的对外跳转链接（包括不限于超链接、二维码、口令等形式），用于传递更多信息，节省甄选时间，结果仅供参考，IT之家所有文章均包含本声明。